FDA adds DVT, PE to apixaban’s approval list

The FDA gave the green light to apixaban as a treatment for deep vein thrombosis (DVT) and pulmonary embolism (PE) and to reduce the risk of DVT and PE recurrence.

Apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) is a direct factor Xa inhibitor. It previously was approved in the U.S. to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and as a prophylaxis of DVT in patients who received hip or knee replacement surgery.

The drug had been approved in Europe for the prevention of DVT and PE in adults who have undergone elective hip or knee replacement surgery; for prevention of stroke and systemic embolism in adults with nonvalvular atrial fibrillation with one or more risk factors; and most recently for the treatment of DVT and PE and the prevention of recurrent DVT and PE in adults.

The FDA based its approval on results from the AMPLIFY (Apixaban after the initial Management of Pulmonary emboLIsm and deep vein thrombosis with First-line therapY) and AMPLIFY-EXT trials. In AMPLIFY, apixaban was found to be comparable to standard care for efficacy with less major bleeding. A recent analysis of AMPLIFY-EXT data showed continuing treatment of either 2.5 mg and 5 mg dose apixaban reduced the risk of recurrent DVT and PE.

Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup